Search results for "metabolic"

showing 10 items of 2205 documents

Commensal Bacterium Rothia aeria Degrades and Detoxifies Gluten via a Highly Effective Subtilisin Enzyme

2020

Celiac disease is characterized by a chronic immune-mediated inflammation of the small intestine, triggered by gluten contained in wheat, barley, and rye. Rothia aeria, a gram-positive natural colonizer of the oral cavity and the upper digestive tract is able to degrade and detoxify gluten in vitro. The objective of this study was to assess gluten-degrading activity of live and dead R. aeria bacteria in vitro, and to isolate the R. aeria gluten-degrading enzyme. Methods: After an overnight fast, Balb/c mouse were fed a 1 g pellet of standard chow containing 50% wheat (and 4% gliadin) with or without 1.6 &times

0301 basic medicinelcsh:TX341-641detoxifymedicine.disease_causedigestive systemBacterial cell structure<i>Rothia</i>Microbiology03 medical and health sciences0302 clinical medicinemedicineZymographydegradationchemistry.chemical_classificationepitopeNutrition and DieteticsbiologyRothia aeria<i>Bacillus</i>food and beveragesnutritional and metabolic diseasesbiology.organism_classificationGlutenneutralizecuredigestive system diseasesEnzyme assay030104 developmental biologychemistryglutencommensalbiology.proteinsubtilisin030211 gastroenterology & hepatologyDigestionGliadinlcsh:Nutrition. Foods and food supplyceliac diseaseBacteriaFood ScienceNutrients
researchProduct

Significance of magnesium in insulin resistance, metabolic syndrome, and diabetes – recommendations of the Association of Magnesium Research e.V.

2017

Magnesium (Mg) depletion is an important and highly prevalent condition in patients with diabetes or precursor states of type-2 diabetes like metabolic syndrome. Mg deficiency increases the risk of developing type-2 diabetes. These recommendations compile present data on the physiology of Mg in carbohydrate metabolism and pathophysiological consequences of Mg depletion for diabetics. Diabetes patients and candidates benefit from four categories of Mg effects: insulin-sensitizing effect, calcium antagonism, stress-regulating and endotheli-um-stabilizing effects. Clinical data with Mg co-medication show improvement of insulin resistance/blood glucose level and reduced long-term vascular damag…

0301 basic medicinemedicine.medical_specialty030109 nutrition & dieteticsbusiness.industryMagnesiumInsulinmedicine.medical_treatmentClinical Biochemistrymagnesium insulin diabeteschemistry.chemical_elementmedicine.diseaseBiochemistryInorganic Chemistry03 medical and health sciencesEndocrinologyInsulin resistancechemistryDiabetes mellitusInternal medicineMedicineMetabolic syndromebusinessTrace Elements and Electrolytes
researchProduct

Coffee and metabolic impairment: An updated review of epidemiological studies

2016

Abstract Background Coffee is one of the most consumed beverages worldwide. In the last years, coffee consumption has been associated with a number of beneficial effects against metabolic impairment. The aim of this narrative review was to report the most updated and comprehensive evidence from epidemiological and experimental studies as well as mechanisms of action of coffee on metabolic impairment. Methods A search in electronic databases (PUBMED and EMBASE) was performed to retrieve systematic and pooled analyses on coffee and diabetes, hypertension, and dyslipidemia. Furthermore, the most accredited hypotheses and mechanisms of action of coffee have been described. Results Coffee consum…

0301 basic medicinemedicine.medical_specialtyAntioxidantmedicine.medical_treatmentMetabolic disordersPhysiologyBlood lipidslcsh:TX341-641030209 endocrinology & metabolismDiabeteCoffee03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCaffeineDiabetes mellitusEpidemiologymedicineFood science030109 nutrition & dieteticsNutrition and Dieteticslcsh:TP368-456business.industryDiabetesMetabolic disordermedicine.diseaselcsh:Food processing and manufactureBlood pressurechemistryObservational studybusinessCaffeinelcsh:Nutrition. Foods and food supplyDyslipidemiaFood ScienceNFS Journal
researchProduct

Systemic treatment of HCC in special populations

2020

Summary Recent years have seen significant progress in the systemic treatment of hepatocellular carcinoma (HCC), including the advent of immunotherapy. While several large phase III trials have provided the evidence for a multi-line treatment paradigm, they have focused on a highly selected group of patients by excluding potentially confounding comorbidities. As a result, high quality evidence for the systemic treatment of HCC in patients with various comorbidities is missing. This review summarises current knowledge on the use of approved medicines in patients with HIV, autoimmune disease, cardiovascular disease, diabetes, fibrolamellar HCC, mixed HCC-cholangiocarcinoma, decompensated cirr…

0301 basic medicinemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentComorbidityDisease03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicineHumansMultiple Chronic ConditionsAutoimmune diseaseHepatologybusiness.industryLiver NeoplasmsConfoundingDisease ManagementImmunotherapymedicine.diseasedigestive system diseasesPortal vein thrombosis030104 developmental biologyHepatocellular carcinoma030211 gastroenterology & hepatologyMetabolic syndromebusinessJournal of Hepatology
researchProduct

Chronic hyponatremia in a patient with renal salt wasting and without cerebral disease: relationship between RSW, risk of fractures and cognitive imp…

2018

Renal salt wasting syndrome (RSW) is defined as a renal loss of sodium leading to hyponatremia and a decrease in extracellular fluid volume (ECV). Differentiation of this disorder from the syndrome of inappropriate antidiuretic hormone secretion (SIADH), a common cause of hyponatremia, can be difficult because both can present with hyponatremia and concentrated urine with natriuresis. Our clinical case about a 78-year-old woman with a recent fracture of the right femur not only confirms that this syndrome can occur in patients without intracranial pathologies (CT documented), but depicts how the hyponatremia caused by RSW can show a chronic, oscillating course. This is an interesting point …

0301 basic medicinemedicine.medical_specialtyChronic hyponatremiaNatriuresis03 medical and health sciences0302 clinical medicineCognitionInternal medicineExtracellular fluidCerebral salt wasting syndromeInternal MedicineMedicineHumansWasting SyndromeRenal Insufficiency ChronicAgedbusiness.industryWasting SyndromeRenal salt wasting syndromeSodiumSIADHfood and beveragesnutritional and metabolic diseasesCerebral salt-wasting syndromemedicine.diseaseChronic hyponatremia030104 developmental biologySyndrome of inappropriate antidiuretic hormone secretionEmergency MedicineCardiologyFemaleDifferential diagnosisbusinessHyponatremia030217 neurology & neurosurgeryNatriuretic peptideHumanHyponatremia
researchProduct

The association of periodontal diseases with metabolic syndrome and obesity

2020

Periodontitis is a multifactorial chronic inflammatory disease associated with dysbiotic plaque biofilms and characterized by progressive destruction of the tooth-supporting apparatus. Globally, it is estimated that 740 million people are affected by its severe form. Periodontitis has been suggested to be linked to obesity and metabolic syndrome. Obesity, defined as excessive fat accumulation, is a complex multifactorial chronic inflammatory disease, with a high and increasing prevalence. Metabolic syndrome is defined as a cluster of obesity, dyslipidemia, hypertension, and dysglycemia. Obesity, metabolic syndrome and periodontitis are among the most common non-communicable diseases and a l…

0301 basic medicinemedicine.medical_specialtyChronic inflammatory diseaseDisease cluster03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansObesityRisk factorPeriodontitisPeriodontal DiseasesMetabolic SyndromePeriodontitisbusiness.industryPublic health030206 dentistrymedicine.diseaseObesity030104 developmental biologyPeriodonticsMetabolic syndromebusinessDyslipidemiaPeriodontology 2000
researchProduct

Expert opinion on the metabolic complications of mTOR inhibitors

2018

Abstract Using mTOR inhibitors (mTORi) as anticancer drugs led to hyperglycemia (12–50%) and hyperlipidemia (7–73%) in phase-III trials. These high rates require adapted treatment in cancer patients. Before initiating mTORi treatment, lipid profile screening should be systematic, with fasting glucose assay in non-diabetic patients and HbA1C in diabetic patients. After initiation, lipid profile monitoring should be systematic, with fasting glucose assay in non-diabetic patients, every 2 weeks for the first month and then monthly. The HbA1C target is ≤ 8%, before and after treatment initiation in known diabetic patients and in case of onset of diabetes under mTORi. LDL-cholesterol targets sho…

0301 basic medicinemedicine.medical_specialtyConsensusEndocrinology Diabetes and MetabolismAtorvastatinAntineoplastic Agents03 medical and health sciences0302 clinical medicineEndocrinologyMetabolic DiseasesNeoplasmsInternal medicineDiabetes mellitusHyperlipidemiamedicineHumansDyslipidemiasFenofibratemedicine.diagnostic_testbusiness.industryTOR Serine-Threonine KinasesHypertriglyceridemianutritional and metabolic diseasesGeneral Medicinemedicine.diseaseHypoglycemia030104 developmental biologySimvastatin030220 oncology & carcinogenesislipids (amino acids peptides and proteins)Lipid profilebusinessPravastatinmedicine.drugAnnales d'Endocrinologie
researchProduct

Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial

2017

Background Limited prospective studies have examined changes in non-alcoholic fatty-liver disease (NAFLD) related serum-metabolites and none the effects of NAFLD-reversion. We aimed to evaluate whether perturbations in metabolites indicate predisposition to NAFLD development and to assess the effects of NAFLD reversion on metabolite profiles. Methods A targeted liquid-chromatography tandem mass-spectrometry metabolic profiling (n = 453 metabolites) approach was applied, using serum from 45 subjects of the PREDIMED study, at baseline and after a median 3.8-year follow-up. NAFLD was determined using the hepatic steatosis index; with three groups classified and studied: Group 1, not characteri…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismMetaboliteMedicine (miscellaneous)lcsh:TX341-641Clinical nutritionBiology03 medical and health scienceschemistry.chemical_compoundFetge--MalaltiesInternal medicineLipid biosynthesisHepatic lipotoxicitymedicineMetabolomicsProspective cohort studylcsh:RC620-627Nutrition and DieteticsFatty acid metabolismResearchFatty livernutritional and metabolic diseasesmedicine.diseasedigestive system diseaseslcsh:Nutritional diseases. Deficiency diseases030104 developmental biologyEndocrinologychemistryLipotoxicityFatty acid metabolismSteatosislcsh:Nutrition. Foods and food supplyNon-alcoholic fatty liver diseaseNutrition & Metabolism
researchProduct

Glycometabolic Alterations in Secondary Adrenal Insufficiency: Does Replacement Therapy Play a Role?

2018

Secondary adrenal insufficiency (SAI) is a potentially life-threatening endocrine disorder due to an impairment of corticotropin (ACTH) secretion from any process affecting the hypothalamus or pituitary gland. ACTH deficit can be isolated or associated with other pituitary failures (hypopituitarism). An increased mortality due to cardiovascular, metabolic, and infectious diseases has been described in both primary and secondary adrenal insufficiency. However, few studies have provided compelling evidences on the underlying mechanism in SAI, because of the heterogeneity of the condition. Recently, some studies suggested that inappropriate glucocorticoid (GCs) replacement therapy, as for dose…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismMini Reviewbody mass index; diabetes mellitus; glucocorticoids; impaired glucose tolerance; insulin resistance; metabolic syndrome; secondary adrenal insufficiency; weight gain030209 endocrinology & metabolismbody mass indexHypopituitarismlcsh:Diseases of the endocrine glands. Clinical endocrinologymetabolic syndromeGrowth hormone deficiencyImpaired glucose tolerance03 medical and health sciences0302 clinical medicineInsulin resistanceEndocrinologyInternal medicineDiabetes mellitusinsulin resistanceMedicineEndocrine systemlcsh:RC648-665glucocorticoidsbusiness.industryweight gainmedicine.disease030104 developmental biologyEndocrinologyimpaired glucose tolerancediabetes mellitussecondary adrenal insufficiencyMetabolic syndromebusinessGlucocorticoidmedicine.drug
researchProduct

Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect

2020

Liraglutide has shown favourable effects on several cardiometabolic risk factors, beyond glucose control. MicroRNAs (miRNAs) regulate gene expression, resulting in post-transcriptional modifications of cell response and function. Specific miRNAs, including miRNA-27b, miRNA-130a, and miRNA-210, play a role in cardiometabolic disease. We aimed to determine the effect of liraglutide on the serum levels of miRNA-27b, miRNA-130a and miRNA-210. Twenty-five subjects with type-2 diabetes mellitus (T2DM), na&iuml

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolismlcsh:QR1-502IncretinType 2 diabetestype-2 diabetes030204 cardiovascular system & hematologyBiochemistryArticlelcsh:Microbiologyliraglutide; microRNAs; type-2 diabetes; cardiometabolic risk; epigenetic03 medical and health sciences0302 clinical medicineInterquartile rangeDiabetes mellitusInternal medicinecardiometabolic riskMedicineMolecular Biologyliraglutidebusiness.industryLiraglutideType 2 Diabetes MellitusMicroRNAmedicine.diseaseMetforminmicroRNAs030104 developmental biologyEndocrinologybusinessHomeostasisepigeneticmedicine.drugMetabolites
researchProduct